Financial Wire

ASXプレビュー:中東情勢の緊迫化による原油価格高騰を受け、オーストラリア株は上昇へ。リオ・ティント・グループは第1四半期の銅換算生産量と鉄鉱石生産量の増加を報告。

-- オーストラリア株式市場は火曜日、ブレント原油価格が5%以上急騰したことを受け、上昇基調で推移する見込みだ。中東情勢の緊迫化と、米イラン停戦協議の停滞によるホルムズ海峡を巡る不確実性の高まりが背景にある。 前日のS&P500種株価指数、ナスダック総合指数、ダウ工業株30種平均はそれぞれ0.2%、0.3%、0.01%下落した。 マクロ経済指標では、ANZ銀行が火曜日に発表したANZ-ロイ・モーガン・オーストラリア消費者信頼感指数は、4月13日から19日の週で0.2ポイント低下し、64.3となった。 企業ニュースでは、リオ・ティント・グループ(ASX:RIO)が火曜日に発表した第1四半期の銅換算生産量が前年同期比9%増加した一方、世界の鉄鉱石生産量は12%増の8,280万トンとなった。 ライナス・レアアース(ASX:LYC)は、第3四半期の売上高が前年同期の1億2300万豪ドルから2億6500万豪ドルに増加し、販売額も1億2460万豪ドルから2億3400万豪ドルに増加したと発表した。 オーストラリアの主要株価指数は月曜日、0.1%(6.4ポイント)上昇し、8953.30で取引を終えた。

Related Articles

Asia

Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%

Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.

$SHA:600930
Asia

National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme

National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.

$ASX:NSR
Asia

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.

$ASX:SPL